Publications by authors named "Kahaku Emoto"
Article Synopsis
- The study aimed to evaluate changes in protein biomarkers following filgotinib treatment in RA patients who did not adequately respond to methotrexate.
- Plasma and serum samples were analyzed from a Phase 3 trial, comparing the effects of filgotinib to adalimumab and placebo on various biomarkers related to inflammation and disease activity over 12 weeks.
- Filgotinib showed significant reductions in inflammatory cytokines and bone turnover biomarkers as early as 4 weeks into treatment, confirming its effectiveness in managing RA symptoms and highlighting its role in JAK/STAT signaling pathways.
Article Synopsis
- The post hoc analysis examined the safety and efficacy of filgotinib in patients with rheumatoid arthritis who had inadequate responses to methotrexate or were methotrexate-naive.
- Patients were classified into two subgroups based on their radiographic progression rates before treatment, with one group showing rapid progression and the other slow progression.
- At 24 and 52 weeks, filgotinib demonstrated better disease control and lower radiographic progression in patients with rapid progression compared to those on placebo or methotrexate, indicating its effectiveness in managing more severe cases of rheumatoid arthritis.
Article Synopsis
- - This study investigated the effectiveness and safety of filgotinib (FIL) in rheumatoid arthritis patients who did not respond well to methotrexate and had four specific poor prognostic factors.
- - Patients were treated with either a placebo, FIL (200 mg or 100 mg), or adalimumab, and the analysis found that those on FIL showed significantly better responses in terms of disease activity at 12 weeks compared to placebo.
- - By 52 weeks, FIL200 not only maintained a greater response compared to adalimumab but also showed less progression in joint damage, with similar tolerability across all treatment groups.
Background: The severe asthma and severe, uncontrolled asthma (SUA) populations in Japan are not well-studied. We investigated the prevalence of continuously treated severe asthma and SUA patients, their disease burden, and the treatment reality via a Japanese health insurance claims database.
Methods: Continuously treated asthma patients (patients prescribed inhaled corticosteroids for asthma ≥4 times in the past year) aged ≥17 years at the index date (latest visit between April 2014 and March 2015 for asthma treatment) were included in this analysis (KEIFU study, UMIN000027695).
Background: Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis.
Methods: We conducted a 52-week, phase 3, double-blind, placebo- and active-controlled trial in which 1307 patients with active rheumatoid arthritis who were receiving background therapy with methotrexate were randomly assigned to one of three regimens in a 3:3:2 ratio: placebo (switched to baricitinib after 24 weeks), 4 mg of baricitinib once daily, or 40 mg of adalimumab (an anti-tumor necrosis factor α monoclonal antibody) every other week. End-point measures evaluated after adjustment for multiplicity included 20% improvement according to the criteria of the American College of Rheumatology (ACR20 response) (the primary end point), the Disease Activity Score for 28 joints (DAS28), the Health Assessment Questionnaire-Disability Index, and the Simplified Disease Activity Index at week 12, as well as radiographic progression of joint damage as measured by the van der Heijde modification of the total Sharp score (mTSS) (range, 0 to 448, with higher scores indicating greater structural joint damage) at week 24.
Objective: To evaluate efficacy and safety, baricitinib [Janus kinase (JAK) 1/JAK2 inhibitor] was compared with placebo in Japanese patients with active rheumatoid arthritis (RA) despite background treatment with methotrexate (MTX).
Methods: This was a phase IIB, double-blind, randomized, placebo-controlled study (clinicaltrials.gov: NCT01469013).